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Abstract

Objective: To conduct the first and only systematic review of the existing literature on head and
neck manifestations of Eosinophilic Granulomatosis with Polyangiitis in order to guide clinical
decision making for the otolaryngologist.
Data Sources: PubMed, Cochrane Library, Scopus and LILACS. Review Methods: A systematic
review of the aforementioned sources was conducted per PRISMA guidelines. Results: From an
initial 574 studies, 28 trials and reports accounting for a total of 1,175 Eosinophilic Granulomatosis
with Polyangiitis patients were included. Amongst clinical and cohort studies, 48.0% to 96.0% of
all included patients presented with head and neck manifestations. In a distinct group of patients
detailed in case reports describing patients presenting with head and neck manifestations on average fulfilled 4.6 American College of Rheumatology diagnostic criteria. Further, 95.8% of reported cases were responsive to steroids and 60% required additional therapy. Conclusion: Otolaryngologists are in a unique position for the early diagnosis and prevention of late complications of
Eosinophilic Granulomatosis with Polyangiitis. The American College of Rheumatology criteria
should be relied upon in the diagnostic work-up. Close surveillance of these patients in a multidisciplinary fashion and with baselines CBCs, chest radiographs and autoimmune labs is often
necessary. Such patients with head and neck manifestations of the disease are nearly always responsive to steroids and often require additional immunosuppressive therapy or surgical intervention in cases of cranial neuropathies, temporal bone involvement and refractory symptoms.
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Introduction

Eosinophilic Granulomatosis with Polyangiitis (EGPA), also known as Churg-Strauss Syndrome,
is a rare systemic vasculitis affecting small and medium-sized vessels of the paranasal sinuses,
lungs and nervous system. Initial presentations of EGPA often present with clinical profiles referable to otolaryngology departments. Otolaryngologists are consequently in a unique position to
diagnose the disease early and prevent late complications. Due to the potential for extensive head
and neck involvement, it is crucial for otolaryngologists to recognize EGPA's characteristic
presentation and play a chief role in the interdisciplinary approach to management. To date there
have been limited reviews of the literature highlighting generalized patient experiences and rare
presentations of EGPA with an otolaryngologic focus.

EGPA clinically manifests in three delineated stages. The disease classically will first present in
a prodromal stage which is characterized by asthmatic episodes, allergic rhinitis, rhinosinusitis and
occasional nasal polyps.1 EGPA's second phase will present with peripheral eosinophilia and eosinophilic infiltration of tissues.2 Lastly, EGPA's third phase will manifest with polyneuropathies
secondary to systemic vasculitis.2 Late debilitating and fatal manifestations of EGPA include: myocarditis, sudden cardiac death, cerebral hemorrhages, ischemic strokes and bowel perforations.2
As this disease course may persist or recur for several years, an otolaryngologist is afford a large
window of time to monitor symptoms and make the diagnosis of EGPA. However this diagnosis
may be difficult due to its variable presentation and lack of definitive objective tests to rule the
disease in or out.

3

Historically multiple organizations have defined EGPA differently; however, the American College of Rheumatology's (ACR's) classification criteria has been widely accepted since the 1990's.
According to the ACR, in order to be classified as EGPA an individual must present with at least
four of six distinct findings: 1) a medical history of asthma, 2) eosinophilia of greater than 10%,
3) mono- or polyneuropathy, 4) non-fixed pulmonary infiltrates, 5) paranasal sinus abnormalities,
or 6) biopsy including an artery, arteriole or venule documenting accumulated eosinophils in extravascular tissue.3

The objective of this systematic review is to review the current literature on EGPA and its otolaryngologic manifestations as well as investigating the role of the otolaryngologist to assist in
early detection of disease. To the authors' knowledge this is the first and only systematic review
of EGPA with a focus on head and neck manifestations.

Methods

Search strategy and selection

We conducted a focused literature review targeting the otolaryngological clinical presentations,
diagnosis, treatments and outcomes of patients with EGPA. The systematic review was conducted
per the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines.4 Studies were evaluated by four independent reviewers in order to minimize appraisal bias.
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Study eligibility and selection criteria were predefined to include: large study groups of general
EGPA patients or case reports of EGPA patients with head and neck presentations. For the purposes of this review, diagnosis of EGPA was dependent upon meeting the ACR definition of the
disease.

Only those clinical trial and cohort reviews that included a generalized EGPA population in which
those patients with specific head and neck manifestations were identified and distinguished were
to be included. Case series and reports of interest would include head and neck manifestations
meeting the above inclusion criteria.

In March 2016 a search was initiated via PubMed, Cochrane Library, Scopus and LILACS databases. Key terms and their derivatives included: otolaryngology, ear, nose, throat, laryngology,
rhinology, otology, cranial nerves, parotid, submandibular gland, sublingual gland, mastoid, paranasal sinuses, neck, churg-strauss syndrome, and eosinophilic granulomatosis with polyangiitis.

Search catalogs were collected and imported into RefWorks software. Exact and close duplicates
were detected and manually reviewed for accuracy before deletion of repeated studies. Concerns
and discrepancies regarding study relevancy between reviewers were discussed amongst all authors to reach a consensus if necessary.

Titles and abstracts of all search results were thoroughly reviewed for relevance and eligibility.
Studies were screened and excluded based upon being: non-head and neck presentations, non-
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English without available translation or non-EGPA specific studies. Studies in question were reviewed in full-text for clarity and excluded based on: overlapping patient populations, insufficient
data, unavailable English full text, or failing to fulfill ACR criteria.

Data collection
Due to the rarity of head and neck manifestations of EGPA data was collected and organized into
two distinct subsets: clinical trials or cohort studies and case report experiences. When available
the following patient information was independently extracted from the relevant clinical trial and
cohort studies: means of selection, population size, mean age, gender, head and neck manifestations, nasal and paranasal sinus histology, ANCA status, treatment and outcome.

Case series and reports meeting inclusion criteria were reviewed for and had the following data
extracted: age, gender, ACR criteria met, non-paranasal head and neck manifestations, ANCA
status, treatment and outcome. When available the source of extravascular eosinophilia and histology was noted. Treatment methods were further divided to steroidal and non-steroidal interventions. Outcomes were recorded with a focus on response to given therapy.

Included studies were evaluated in terms of study design, level of evidence and risk of bias. Level
of evidence was determined by the Oxford Centre for Evidence-Based Medicine 2011 Levels of
Evidence.5 Risk of bias were assessed using the Cochrane Collaboration's tool for assessing risk
of

bias

for

a

grading

of

low,

high

or

unclear

risk

of

bias.6

Results
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Study Results

In our search we collected a total of 574 articles through the above named databases along with
additional articles identified through references of seed studies used in introductory background
research. Ultimately the results of 1 clinical trial, 6 retrospective cohort studies, 2 prospective
cohort studies, 2 case series and 17 case reports accounting for a total of 1,175 EGPA patients
were included for systematic review.7-34

Figure 1. PRISMA flow diagram for study inclusion

Table 1. Included study designs, levels of evidence and biases

As seen in table 1, of the 28 studies meeting our inclusion criteria levels of evidence ranged from
2 to 4. Risk of bias was either low or unclear in all studies. Unclear risk of bias presented as
attrition bias due to insufficiently addressed incomplete outcome data in 3 studies. Reporting bias
was unclear in 2 studies that provided insufficient clinical selection criteria.

Clinical trial and cohort study results

Table 2. Clinical trial and cohort study designs, demographics and symptoms

As seen in table 2, individual study patient population sizes ranged from 28 to 383 with a median
of 101 patients. The mean age of patient populations ranged from 49.1 to 51.9. Male to female
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ratio ranged from 58:43 to 39:54. Of these patients, documented head and neck manifestations
included: various rhinologic conditions including sinusitis, nasal polyps, rhinitis nasal crusting and
nasal obstruction along with otitis media, sensorineural hearing loss and facial nerve palsies. Of
the total number of patients included in each individual study, 48.0% to 96.0% of patients presented with some head and neck involvement.

Table 3. Clinical trial and cohort study diagnostic findings, treatments and outcomes

As highlighted in table 3, patients with documented nasal or paranasal sinus biopsies demonstrated
eosinophilic infiltration in 35% to 100% of samples. None of said biopsies had evidence of necrotizing vasculitis or eosinophilic granulomas. In these studies, the presence or absence of a
blood vessel was not noted. Additionally the site of the biopsy collected was not specified beyond
the general categories of “nasal cavity and paranasal sinuses” or “sinus or nasal mucosa”.9,10

All patients in each population received some form of steroids. Cyclophosphamide was the second
most common offered therapy and received in 49.5% to 71% of cases in which documentation was
available. Additional common therapies included: azathioprine, methotrexate, rituximab, mycophenolate mofetil, intravenous immunoglobulin, leflunomide, anti-TNF alpha and plasma exchange. Insufficient data was available to be extracted regarding medication choice or dosage to
correlate therapy with clinical presentation and outcome.

Case series and reports results
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Nineteen publications accounted for 25 total patients with unique head and neck manifestations.
Included patients had a mean age of 52.16 and male to female ratio of 2:5. Patients presented
meeting an average of 4.6 ACR criteria. All but 1 patient presented with evidence of asthma and
90% of patients presented with extravascular eosinophilia on histology. Paranasal sinus abnormalities, eosinophilia, neuropathy and non-fixed pulmonary infiltrates presented in 88.%, 88.0%,
56.0%, and 48.0% of patients respectively. Of patients identified, 17 had known ANCA status of
which 64.7% were ANCA positive.

Head and neck manifestations varied greatly and involved all systems. Such presentations included: recurrent laryngeal polyposis, anosmia, mastoiditis, intracranial abscesses and a diversity
of cranial neuropathies. In the evaluation of these patients, extravascular eosinophilic histology
was demonstrated in a diversity of head and neck specific biopsy sites as described by the case
reports and series authors such as: laryngeal polyps, the ethmoid sinus, salivary glands and the
mastoid.28, 17, 25 In meeting ACR criteria, mastoid biopsies revealed eosinophilic granulomatous
tissue while histology was limited to only eosinophilic infiltration or necrosis in all other above
noted head and neck sites.

All but one (96.0%) of included patients with sufficient data received steroids and were found to
be responsive in 95.8% of cases. Prednisone was the most commonly offered steroid (56.0%)
followed by methylprednisolone (24.0%). The most common inducing dose of prednisone was 60
mg daily and tapered dosages ranged from 4 mg to 10 mg daily. Inducing dosages were administered from 5 days to 6 weeks. Additional medical or surgical therapy was offered in 56.0% of
cases. Additional immunosuppressant therapy including cyclophosphamide, azathioprine and
methotrexate were provided in 28.0% of cases. All included patients had either stabilization or
9

resolution of presenting symptoms. Of the 5 patients receiving cyclophosphamide 3 had resolution
of symptoms, 1 experienced partial resolution of symptoms and 1 died of secondary pulmonary
infection. Of the 3 patients receiving azathioprine, 2 achieved remission and 1 experienced partial
resolution of symptoms. The 1 patient treated with methotrexate had resolution of symptoms at 1
year.

Discussion

From its seemingly indolent initial presentations to its debilitating advanced cardiac, neurological
and gastrointestinal manifestations, the diagnosis and treatment of EGPA poses a clinical challenge
to otolaryngologists. Through reviewing the existing literature we were able to construct a clinical
profile of EGPA patients presenting with head and neck manifestations both common and rare.
Data was extracted through 28 studies of varied designs including: clinical trials, prospective and
retrospective cohort studies along with cases series and reports. Levels of data ranged from 2 to 4
with varying degrees of bias risk. Our review was potentially limited by the inherent quality of
included studies. Many of the studies in the field were observational and pooled from various
patient databases. Patient populations may be influenced by level of disease severity as well as
the subsidiary medical departments being referred to at each medical center.

Patient group populations were consistent in age and gender ratios to one-another and previous
reports.35 Study samples had large variations in proportion of patients with head and neck manifestations. Differences may be attributed to the varied departments referred to within each group
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or the definitions of head and neck manifestations by each study. Further, ANCA positive status
varied. A majority of studies failed to demonstrate an association between patients with head and
neck manifestations and ANCA status compared to the general EGPA population. This suggests
that while a positive ANCA status may be helpful in the work-up of EGPA, it is often negative,
not required in establishing a diagnosis of EGPA and has an unclear role in the head and neck
phenotype of EGPA patients.

Case reports described varying degrees of severity and unique presentations of EGPA. These
patients on average exceeded the minimum diagnostic criteria per the ACR guidelines suggesting
that a CBC, PFT, EMG, tissue biopsy and full head and neck physical exam are all potentially
necessary in the diagnosis of EGPA.

In all studies reviewed, no nasal or paranasal sinus biopsies revealed any eosinophilic granulomas
and only one demonstrated evidence of necrotizing vasculitis. It is important to note that while
EGPA is regarded as a vasculitis, biopsies are often marked by a non-destructive eosinophilic
vessel wall infiltration.36 While many did demonstrate an eosinophilic infiltration, this is a common histologic finding of upper airway tissue in atopic disease processes.

In understanding the questionable significance of biopsy findings, otolaryngologists would benefit
from more objectively defined diagnostic guidelines. Although it is stated in the ACR guidelines
that a blood vessel is necessary to be included in a biopsy, further elaboration would assist in
diagnosing EGPA. For instance a minimum eosinophil concentration, an eosinophil to neutrophil
ratio, a maximum eosinophil proximity to the vessel and a defined eosinophil pattern in relationship to the vessel would assist in determining the context of a sample. These descriptions would
11

also help define the significance of “eosinophilic infiltration” and “extravascular eosinophils”
which are not currently objectively defined in guidelines.

In the setting of equivocal histopathologic findings, an otolaryngologist should also look for concomitant eosinophilia, a longstanding history of refractory or adult onset asthma and sinusitis along
with any neuropathies. Moreover, even if nasal or paranasal sinus biopsy demonstrates extravascular eosinophilic histology, one should consider further biopsies when additional body system
involvement is suspected to further substantiate the nasal and paranasal sinus findings. Of note,
some authors have broadened the diagnostic threshold by proposing the limited form of EGPA.
Such cases highlight presentations which fail to fulfill the clinical and histopathological characteristics of EGPA.37 Although this concept is applied to earlier diagnostic criteria, it is important to
recognize EGPA defined by the ACR criteria as a disease which exists on a continuum. Moreover,
as otolaryngologists often encounter patients in the earlier prodromal stages of EGPA, neuropathies and eosinophilia may not yet be present.

Given our finding that eosinophilia and pulmonary infiltrates are common manifestations which
follow asthma and polyposis, we recommend evaluation with a pre-operative or outpatient CBC
with differential as well as a chest radiograph in the presence of any pulmonary symptoms to
provide a baseline for patients with a high index of suspicion. Additionally we recommend basic
autoimmune labs including ANA and ANCA in such patient. Although not a component of the
ACR criteria or directly associated with head and neck manifestation severity, autoimmune findings are effective in ruling out other vasculitides and narrowing a diagnosis of EGPA. We also
recommend when such patients undergo FESS for nasal polyposis, close communication with pathology is necessary to ensure the inclusion of blood vessels, to closely evaluate for eosinophilic
12

patterns and to rule out infection or malignancy. Due to the prevalence of chronic rhinosinusitis
with polyposis in many otolaryngology practices, a multidisciplinary approach is often necessary
prior to such a work-up. A benefit risk assessment is a strong area for future study given the
constraints of the existing data.

In the treatment of patients with head and neck manifestations we see that nearly all were responsive to steroids and often required additional immunotherapy or surgical interventions. Ninety six
percent of patients received some form of steroid. Patients on steroids alone had resolution of both
clinical symptoms and laboratory abnormalities in 14 of 16 (87.5%) of cases. A common recommendation involved initial inducing dosages of 1 mg/kg of prednisone daily for 1 to 6 months then
tapered to 4 to 10 mg of prednisone daily.

Patients with refractory symptoms, neuropathies and those with temporal bone involvement often
required additional immunosuppressive therapy. The most common additional therapy offered
with cyclophosphamide, often received in 6 to 12 pulses. Other immunosuppressants included
azathioprine, methotrexate, rituximab and mycophenolate mofetil. Those receiving additional immunotherapy had resolution in 5 of 8 (62.5%) cases.

Ultimately, despite medical management trends, inadequate dosing and response information exists in drawing definitive recommendations for both steroid and immunosuppressive therapies.
Additionally, future studies would benefit from objectively defining response to therapy and with
consideration to biologic markers

Conclusion
13

Given the diagnostic challenge of EGPA, an otolaryngologist must maintain a high index of suspicion for the disease given its characteristic constellation of laboratory values, histologic findings
and clinical manifestations which in isolation are often seemingly ubiquitous. Early diagnosis and
treatment through multidisciplinary collaboration amongst otolaryngologists on the front line of
treatment along with pulmonologists, allergists, immunologists, pathologists and rheumatologists
is key in preventing widespread neuropathies and multi-system involvement.

Based on our review of previous otolaryngologists’ experiences with EGPA, we recommend that
patients presenting with both nasal polyposis and asthma undergo further investigation. Increased
suspicion should be given to those patients with adult-onset asthma, poorly controlled asthmatic
symptoms and those with recurrent nasal polyposis despite corticosteroid or surgical interventions.

Given our finding that eosinophilia and pulmonary infiltrates are common manifestations which
follow asthma and polyposis, we recommend evaluation with a pre-operative or outpatient CBC
with differential as well as a chest radiograph in the presence of any pulmonary symptoms to
provide a baseline for the patient. Additionally we recommend basic autoimmune labs including
ANA and ANCA in such patients with a high suspicion for EGPA. Although not a component of
the ACR criteria or directly associated with head and neck manifestation severity, autoimmune
findings are effective in ruling out other vasculitides and narrowing a diagnosis of EGPA. We
also recommend when such patients undergo FESS for nasal polyposis, close communication with
pathology is necessary to ensure the inclusion of blood vessels, to closely evaluate for eosinophilic
patterns and to rule out infection or malignancy.
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Ultimately EGPA is a rare process and little data exists in specifically guiding the otolaryngologic
management of this disease. This is the first only systematic review of the existing literature with
a head and neck focus. Due to a paucity of existing data for meta-analysis a treatment algorithm
or dosage recommendations for corticosteroid and antimetabolite treatment cannot be reached at
this time and is a fertile area for future study.
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Table 1. Included study designs, levels of evidence and biases

Study Type

Level of Evidence

Risk of Bias

Al-Ammar (2009)

Case report

4

Low

Anar (2011)

Case report

4

Low

Bacciu (2006)

Retrospective cohort study

3

Low

Bili (1999)

Case series

4

Unclear reporting bias

Boin (2006)

Case report

4

Low

Comarmond (2013)

Retrospective cohort study

3

Unclear attrition bias

Durel (2015)

Retrospective cohort study

3

Low

Fernandes (2014)

Case report

4

Low

Healy (2012)

Retrospective cohort study

3

Unclear attrition bias

Ishiyama (2001)

Case series

4

Low

Martinez Del Pero (2008)

Case report

4

Low

Moor (2002)

Case report

4

Low

Moosig (2013)

Retrospective cohort study

3

Low

Ovidia (2009)

Case report

4

Low

Park (2015)

Case report

4

Low

Ribi (2008)

Clinical trial

2

Unclear reporting bias

Sablé-Fourtassou (2005)

Prospective cohort study

3

Unclear attrition bias

Saka (2007)

Case report

4

Low

Samson (2013)

Prospective cohort study

3

Low

Sinico (2005)

Retrospective cohort study

3

Low

Tallab (2014)

Case report

4

Low

Trovoli (2013)

Case report

4

Low

Visentin (2012)

Case report

4

Low

Ozaki (2012)

Case report

4

Low

Plaza (2001)

Case report

4

Low
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Sale (1981)

Case report

4

Low

Byun (2014)

Case report

4

Low

Mazzantini (1997)

Case report

4

Low
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Table 2. Clinical trial and cohort study designs, demographics and symptoms

Selection
Patients Mean
(n)

age

Gender

ENT

male/

Involvement

female

no. (%)

ENT Manifestations
Allergic rhinitis, sinusi-

Retrospective review of all

tis, nasal polyps, otitis

Bacciu

CSS patients in single study

media, SNHL, facial

(2006)

group from 1997 to 2004.

Comar-

Retrospective review of pa-

mond

tients in a single cohort from

(2013)

1957 to June 2009

28

51.3

11/10

21 (75%)

199/18
383

50.3

4

nerve palsy

Sinusitis, rhinitis, nasal
184 (48.0%)

polyps

Retrospective review of patients identified in 3 tertiary
Durel

centers databases for from

(2015)

1990 to 2011

Sinusitis, rhinitis, nasal
101

49.2

58/43

97 (96.0%)

polyps, nasal obstruction

93

-

-

59 (63.4%)

Sinusitis

Retrospective review of cases
Healy

reported to FDA from 1997 to

(2012)

2003
Retrospective cohort study of

Sinusitis, nasal mucosa

cases documented at a single

inflammation, nasal

Moosig

referral center from 1990 to

polyps, middle ear infec-

(2013)

2009

150

49.1

76/74

140 (93.3%)

tion

23

Multicenter screening of paRibi

tients diagnosed with CSS

(2008)

from 1994 to 2005.

72

51.7

38/34

50 (69.4%)

Sinusitis

Multi-center cohort study of
French Vasculitis Study
Group and European VascuSablé-

litis Study Group patients en-

Fourtassou

rolled in prospective trials

(2005)

from 1995 to 2002.

Sinusitis, rhinitis, nasal
112

52

55/57

83 (74.1%(

polyps, nasal obstruction

118

51.9

64/54

88 (74.6%)

Sinusitis, crusting, otitis

93

51.6

39/54

72 (77.4%)

Sinusitis

Clinical reports of patients enrolled in 2 prospective, ranSamson

domized open label clinical

(2013)

trials from 1994 to 2005)

Retrospective review of
ANCA tested patients identified among internal medicine
Sinico

departments in 4 general hos-

(2005)

pitals from 1989 to 2004.
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Table 3. Clinical trial and cohort study diagnostic findings, treatments and outcomes

ANCA+:

Bacciu
(2006)

No. All (%)

Nasal and paranasal

No. ENT (%)

sinus biopsies

10 (47.6%)

Comarmond
(2013)

108 (28.2%)
64 (34.8%)

Treatment

Outcome

5: 100% eosino-

-CS and nonspecified immu-

philic polyposis or

nosuppressive treatment in

-No head and neck manifesta-

infiltrates.

all cases

tion relapses; no mortalities.

23: 35% granu-

-Vasculitis relapse in 97;

loma, necrotizing

asthma flares, sinusitis or in-

vasculitis or eosino- -383 CS, 217 CYP; 98 AZA;

creased eosinophilia in 72;

philic infiltration.

236 required maintenance CS

26 MTX; 3 rituximab.
-101 CS; 45 CYP.
-Maintenance therapy: 29 CS
alone; 24 AZA; 22 rituxi-

Durel
(2015)
Healy
(2012)

43 (42.5%)
41 (42.3%)

mab; 15 mycophenolate mo-

fetil; 1 MTX;1 IVIg

-74 with complete remission.

-

-

-

15 (16.1%)
9 (15.3%)

-150 CS; 107 CYP; 105
MTX; 49 AZA; 32 leflunomide; 17 interferon alpha; 10
Moosig
(2013)

45 (30%)
41 (29.3%)

anti-TNF alpha; 1 rituximab;
-

5 IVIg.

-70 in remission.
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Ribi
(2008)

29 (40.3%)
- (-%)

13: 9 eosinophilic
infiltration.

-77 on CS; 5 on AZA and 7 on
-72 CS; 10 AZA; 9 CYP.

CYP with remission.

-Mild disease: CS alone
SabléFourtassou
(2005)

-Severe disease received
43 (38.4%)
36 (43.4%)

steroids along with 6 to 12
-

pulses of CYP therapy.

-102 in remission.

-Mild disease CS alone
Samson
(2013)

48 (40.7%)
- (-%)

-

-Severe disease CS with 6 to

-34 in remission. Overall sur-

12 pulses of CYP.

vival of 90% at 7 years.

-93 CS; 42 CYP; 5 MTX, 1
Sinico
(2005)

35 (37.6%)
27 (37.5%)

AZA, 1 IVIg; 4 and plasma
-

exchange.

- 5 year survival rate of 95.1%

Abbreviations: ANCA+, Anti-neutrophil cytoplasmic antibody positive; AZA, Azathioprine; CS, corticosteroids;
CYP, cyclophosphamide; IVIg, intravenous immunoglobulin; MTX, methotrexate
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Figure legend
Figure 1. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow
diagram for study inclusion and exclusion.
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